PP
NAVB

PDS Planning’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

PDS Planning’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,565
Closed -$2.22K – 309
2022
Q4 		$2.22K Hold
10,565
– – ﹤0.01% 225
2022
Q3 		$3K Hold
10,565
– – ﹤0.01% 203
2022
Q2 		$8K Buy
+10,565
New +$8.97K ﹤0.01% 215
2018
Q3 		– Sell
-1,798
Closed -$8K – 85
2018
Q2 		$8K Hold
1,798
– – 0.01% 75
2018
Q1 		$13K Buy
+1,798
New +$13.4K 0.01% 74

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

PDS Planning's NAVB Position: Q1 2023 in Review

PDS Planning sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2023, closing a stake of 10,565 shares — an estimated $2.22K sold.

PDS Planning first reported a position in NAVB in Q1 2018 and held it in 5 quarters. The position peaked at $13K in Q1 2018. 30 funds tracked by Wall St. Rank hold NAVB as of Q1 2023.

  • PDS Planning reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2023 after selling out during the quarter.
  • PDS Planning sold 10,565 Navidea Biopharmaceuticals Inc. shares in Q1 2023, an estimated $2.22K.
  • PDS Planning first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2018 and held it in 5 quarters.
  • PDS Planning's Navidea Biopharmaceuticals Inc. position peaked at $13K in Q1 2018.
  • 30 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2023.

Based on PDS Planning's 13F filing for Q1 2023, filed 2 May 2023.